Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

CytoDyn settles legal dispute with former chief medical officer

By Brian Buntz | May 23, 2022

CytoDynThe biotech CytoDyn (OTCQB:CYDY) has resolved a legal dispute with Dr. Richard Pestell, the company’s former medical officer who had been “fired with cause” in July 2019.

Today, CytoDyn announced that it had reached a “non-cash settlement” with Dr. Pestell, agreeing to release 8.3 million shares of its stock held in escrow.

In August 2019, the Australian oncologist and endocrinologist Pestell filed a legal complaint with claims related to wage collection, breach of contract, declaratory judgment, wage collection and defamation.

Richard Pestell

Dr. Richard Pestell [Image courtesy of Wikipedia]

As part of its settlement with Pestell, CytoDyn will also transfer assets acquired from ProstaGene in 2018.

Pestell was the founder and CEO of ProstaGene from February 2011 to November 2018.

A 2018 SEC document cites Pestell as the “Stockholder” of ProstaGene, while Pestell served as vice chairman of the board, chief medical officer and board member at CytoDyn from September 2018 to Jul 2019.

The company also agreed to offer seven million shares of its stock at $0.37 per share.

CytoDyn also noted that it was “exploring ways in which Dr. Pestell can reengage with the Company to help realize (lead candidate and CCR5 inhibitor) leronlimab’s full potential in oncology.”

CytoDyn also stated in a news release that it “regrets Dr. Pestell’s departure from the Company and the subsequent public statements made by its former CEO about Dr. Pestell.”

“We are pleased to resolve this matter as part of our comprehensive efforts to restore credibility with the medical and scientific communities,” said Antonio Migliarese, chief financial officer and interim president, in a news release. “We look forward to the opportunity to utilize Dr. Pestell’s expertise to further the development of leronlimab.”

CYDY shares ticked up 7% to $0.34 in afternoon trading.


Filed Under: Drug Discovery, Oncology
Tagged With: CytoDyn
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
Measuring Psilocybin Magic Mushroom Micro Doses in Laboratory for A Scientific Experiment
After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE